Prophylactic Sublingual Immunization with Mycobacterium tuberculosis Subunit Vaccine Incorporating the Natural Killer T Cell Agonist Alpha-Galactosylceramide Enhances Protective Immunity to Limit Pulmonary and Extra-Pulmonary Bacterial Burden in Mice

Prophylactic Sublingual Immunization with Mycobacterium tuberculosis Subunit Vaccine Incorporating the Natural Killer T Cell Agonist Alpha-Galactosylceramide Enhances Protective Immunity to Limit Pulmonary and Extra-Pulmonary Bacterial Burden in Mice

Infection by Mycobacterium tuberculosis (Mtb) remains a major global concern and the available Bacillus Calmette-Guerin (BCG) vaccine is poorly efficacious in adults. Therefore, alternative vaccines and delivery strategies focusing on Mtb antigens and appropriate immune stimulating adjuvants are nee...

Full description

Bibliographic Details
Main Authors:	Arshad Khan, Shailbala Singh, Gloria Galvan, Chinnaswamy Jagannath, K. Jagannadha Sastry
Format:	Article
Language:	English
Published:	MDPI AG 2017-12-01
Series:	Vaccines
Subjects:	tuberculosis vaccine mucosal immunity sublingual vaccination natural killer T cells alpha-galactosylceramide subunit vaccine antigen 85B and ESAT-6 TH1 immune responses
Online Access:	https://www.mdpi.com/2076-393X/5/4/47

Similar Items

B Cell-Based Vaccine Transduced With ESAT6-Expressing Vaccinia Virus and Presenting α-Galactosylceramide Is a Novel Vaccine Candidate Against ESAT6-Expressing Mycobacterial Diseases
by: Bo-Eun Kwon, et al.
Published: (2019-10-01)

Enhancement of Mucosal Immunogenicity of Viral Vectored Vaccines by the NKT Cell Agonist Alpha-Galactosylceramide as Adjuvant
by: Shailbala Singh, et al.
Published: (2014-10-01)

Buccal and Sublingual Vaccines: A Review on Oral Mucosal Immunization and Delivery Systems
by: Valeria Trincado, et al.
Published: (2021-10-01)

Evaluating α-galactosylceramide as an adjuvant for live attenuated influenza vaccines in pigs
by: Bianca L. Artiaga, et al.
Published: (2022-08-01)

The Adjuvant of α-Galactosylceramide Presented by Gold Nanoparticles Enhances Antitumor Immune Responses of MUC1 Antigen-Based Tumor Vaccines
by: Liu Y, et al.
Published: (2021-01-01)

Single-dose Ag85B-ESAT-6 loaded–poly(lactic-co-glycolic acid) nanoparticles confer protective immunity against tuberculosis
by: Malik A, et al.
Published: (2019-05-01)

Vectorized Delivery of Alpha-GalactosylCeramide and Tumor Antigen on Filamentous Bacteriophage fd Induces Protective Immunity by Enhancing Tumor-Specific T Cell Response
by: Rossella Sartorius, et al.
Published: (2018-06-01)

Simultaneous Immunization with Multiple Diverse Immunogens Alters Development of Antigen-Specific Antibody-Mediated Immunity
by: Kelsey A. Pilewski, et al.
Published: (2021-08-01)

Duration of immunity against heterologous porcine parvovirus 1 challenge in gilts immunized with a novel subunit vaccine based on the viral protein 2
by: Beatriz Garcia-Morante, et al.
Published: (2020-06-01)

Subunit Vaccine ESAT-6:c-di-AMP Delivered by Intranasal Route Elicits Immune Responses and Protects Against Mycobacterium tuberculosis Infection
by: Huanhuan Ning, et al.
Published: (2021-03-01)

Preclinical Evaluation of TB/FLU-04L—An Intranasal Influenza Vector-Based Boost Vaccine against Tuberculosis
by: Anna-Polina Shurygina, et al.
Published: (2023-04-01)

Lung memory T-cell response in mice following intranasal immunization with influenza vector expressing mycobacterial proteins
by: A.-P. S. Shurygina, et al.
Published: (2020-08-01)

Respiratory Syncytial Virus F Subunit Vaccine With AS02 Adjuvant Elicits Balanced, Robust Humoral and Cellular Immunity in BALB/c Mice
by: Yu Zheng, et al.
Published: (2020-09-01)

Characterization of a Glycolipid Synthase Producing α-Galactosylceramide in <i>Bacteroides fragilis</i>
by: Marc Caballé, et al.
Published: (2022-11-01)

Intranasal immunization with a single dose of the fusion protein formulated with a combination adjuvant induces long-term protective immunity against respiratory syncytial virus
by: R. Garg, et al.
Published: (2017-12-01)

Immunogenicity and Vaccine Potential of InsB, an ESAT-6-Like Antigen Identified in the Highly Virulent Mycobacterium tuberculosis Beijing K Strain
by: Woo Sik Kim, et al.
Published: (2019-02-01)

Activation of Invariant Natural Killer T Cell Subsets in C57BL/6J Mice by Different Injection Modes of α-galactosylceramide
by: Ming Meng, et al.
Published: (2020-02-01)

Comparison of oseltamivir and α-galactosylceramide for reducing disease and transmission in pigs infected with 2009 H1N1 pandemic influenza virus
by: Darling Melany de C. Madrid, et al.
Published: (2022-10-01)

Prophylactic Cancer Vaccines Engineered to Elicit Specific Adaptive Immune Response
by: Davis W. Crews, et al.
Published: (2021-03-01)

The Influence of Invariant Natural Killer T Cells on Humoral Immunity to T-Dependent and -Independent Antigens
by: Mark L. Lang
Published: (2018-02-01)

Intranasal boosting with RBD-HR protein vaccine elicits robust mucosal and systemic immune responses
by: Li Chen, et al.
Published: (2024-07-01)

Vaccination inducing durable and robust antigen-specific Th1/Th17 immune responses contributes to prophylactic protection against Mycobacterium avium infection but is ineffective as an adjunct to antibiotic treatment in chronic disease
by: Ju Mi Lee, et al.
Published: (2022-12-01)

Comparative evaluation of protective immunity against Francisella tularensis induced by subunit or adenovirus-vectored vaccines
by: Mengsu Zhao, et al.
Published: (2023-05-01)

Optimizing the Boosting Schedule of Subunit Vaccines Consisting of BCG and “Non-BCG” Antigens to Induce Long-Term Immune Memory
by: Wei Lv, et al.
Published: (2022-04-01)

Immunization Basics and Case-Based Discussion
by: Julia Belkowitz, et al.
Published: (2014-12-01)

Targeting Natural Killer Cells for Improved Immunity and Control of the Adaptive Immune Response
by: Stephen Pierce, et al.
Published: (2020-05-01)

Vaccine development for pathogenic fungi: current status and future directions
by: Jéssica L. Chechi, et al.
Published: (2023-12-01)

Transcriptomic analysis of the innate immune signatures of a SARS-CoV-2 protein subunit vaccine ZF2001 and an mRNA vaccine RRV
by: Qian Wang, et al.
Published: (2022-12-01)

High-Titer Neutralizing Antibodies against the SARS-CoV-2 Delta Variant Induced by Alhydroxyquim-II-Adjuvanted Trimeric Spike Antigens
by: Claudio Counoupas, et al.
Published: (2022-02-01)

Co-Delivery of the Human NY-ESO-1 Tumor-Associated Antigen and Alpha-GalactosylCeramide by Filamentous Bacteriophages Strongly Enhances the Expansion of Tumor-Specific CD8+ T Cells
by: Roberta Manco, et al.
Published: (2023-03-01)

GRAZAX®: a sublingual immunotherapy vaccine for Hay fever treatment: from concept to commercialization
by: Domingo Barber, et al.
Published: (2019-12-01)

Oral immunization with cholera DNA vaccine employing microencapsulation delivery system
by: Nograles, Nadine Hayudini
Published: (2013)

Aspects of Phage-Based Vaccines for Protein and Epitope Immunization
by: Marco Palma
Published: (2023-02-01)

Rational Design of Antigen Incorporation Into Subunit Vaccine Biomaterials Can Enhance Antigen-Specific Immune Responses
by: Alexandra N. Tsoras, et al.
Published: (2020-07-01)

Clinical evaluation of a sub-lingual vaccine for prevention of exacerbations in COPD
by: P.D. Nadig
Published: (2016-02-01)

Modulation of Immune Responses to Influenza A Virus Vaccines by Natural Killer T Cells
by: John P. Driver, et al.
Published: (2020-10-01)

Oral inactivated whole cell vaccine for mucosal immunization: ETVAX case study
by: Richard I. Walker, et al.
Published: (2023-03-01)

Structure-Function Implications of the Ability of Monoclonal Antibodies Against α-Galactosylceramide-CD1d Complex to Recognize β-Mannosylceramide Presentation by CD1d
by: Katharine Clark, et al.
Published: (2019-10-01)

ASSESSMENT OF ATTITUDES TOWARDS IMMUNIZATION IN DIFFERENT GROUPS OF POPULATION OF THE RUSSIAN FEDERATION
by: N. I. Briko, et al.
Published: (2017-04-01)

Subunit vaccines for Acinetobacter baumannii
by: Ning Yang, et al.
Published: (2023-01-01)